SCHEMBL3748880

SCHEMBL3748880

C=C1C(=C)[C@H]2[C@@H]3CCC4=CC(=NO)CC[C@]4(C)[C@@H]3CC[C@]2(C)C1C#N

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AR P10275 4/20 0.44
ESR1 P03372 1/20 0.44
ESR2 Q92731 1/20 0.44
CYP3A4 P08684 5/20 0.40
LMNA P02545 5/20 0.40
TSHR P16473 4/20 0.40
SHBG P04278 4/20 0.40
MAPT P10636 4/20 0.40
CYP17A1 P05093 4/20 0.40
MAPK1 P28482 3/20 0.40
NR3C1 P04150 3/20 0.40
PGR P06401 3/20 0.40
SERPINA6 P08185 3/20 0.40
GPBAR1 Q8TDU6 3/20 0.40
SIGMAR1 Q99720 3/20 0.40
SMN1; SMN2 Q16637 3/20 0.40
CYP2C9 P11712 2/20 0.40
HIF1A Q16665 2/20 0.40
ALDH1A1 P00352 2/20 0.40
KDM4E B2RXH2 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3744154 0.84 CYP17A1 (0.56) ARCYP3A4LMNATSHRSHBG
SCHEMBL3747281 0.84 CYP17A1 (0.56) ARCYP3A4LMNATSHRSHBG
SCHEMBL3748877 0.76 SHBG (0.42) ARESR1ESR2CYP3A4LMNA
SCHEMBL3748874 0.76 SHBG (0.42) ARESR1ESR2CYP3A4LMNA
SCHEMBL3363558 0.74 CYP19A1 (0.70) ARESR1ESR2CYP3A4LMNA
SCHEMBL26333875 0.74 CYP19A1 (0.70) ARESR1ESR2CYP3A4LMNA
SCHEMBL3748492 0.73 CYP19A1 (0.55) CYP3A4LMNAMAPTNR3C1PGR
SCHEMBL12029019 0.72 CYP3A4 (0.74) ARCYP3A4LMNATSHRSHBG
SCHEMBL11139019 0.72 CYP3A4 (0.74) ARCYP3A4LMNATSHRSHBG
SCHEMBL12029018 0.72 CYP3A4 (0.74) ARCYP3A4LMNATSHRSHBG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100292184-A1 17BETA-CYANO-19-ANDROST-4-ENE DERIVATIVE, ITS USE AND MEDICAMENTS COMPRISING THE DERIVATIVE BAYER SCHERING PHARMA AG (DE) 2010-11-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100292184-A1 17BETA-CYANO-19-ANDROST-4-ENE DERIVATIVE, ITS USE AND MEDICAMENTS COMPRISING THE DERIVATIVE HSD17B11, HSD17B7, NR5A1 AR 73/4885ESR1 42/4885ESR2 34/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.